New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
NCT ID NCT06107868
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This early-phase study tests a new investigational drug (RP-6306) combined with two standard chemotherapies (carboplatin and paclitaxel) in people with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find the safest dose and see if the combination can shrink tumors or slow disease progression. Only 6 participants are enrolled, and all have cancers that no longer respond to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.